Sutro shells out latest update on ovarian cancer treatment, plans for pivotal trial

Sutro Biopharma gave a Phase I update on its antibody-drug conjugate for ovarian cancer Monday afternoon, as it plans for a Phase II/III trial in the second quarter of 2023.